

# Roberto Giacomelli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7502015/roberto-giacomelli-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

293  
papers

8,130  
citations

52  
h-index

75  
g-index

324  
ext. papers

9,844  
ext. citations

4.9  
avg, IF

5.98  
L-index

#	Paper	IF	Citations
293	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts.. <i>Computational and Structural Biotechnology Journal</i> , <b>2022</b> , 20, 471-484	6.8	0
292	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases.. <i>Clinical Rheumatology</i> , <b>2022</b> , 1	3.9	0
291	Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis.. <i>Scientific Reports</i> , <b>2022</b> , 12, 5125	4.9	0
290	Development and Implementation of the AIDA International Registry for Patients With Still's Disease.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 878797	4.9	0
289	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> ,	2.2	
288	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis.. <i>Scientific Reports</i> , <b>2022</b> , 12, 7498	4.9	1
287	Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. <i>Autoimmunity Reviews</i> , <b>2022</b> , 103114	13.6	1
286	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- $\beta$ and IL-6. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 622	5.2	0
285	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	8
284	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , <b>2021</b> , 1	3.9	1
283	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. <i>Joint Bone Spine</i> , <b>2021</b> , 89, 105299	2.9	2
282	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 615656	8.4	1
281	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102750	13.6	18
280	Endothelial-to-mesenchymal transition in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , <b>2021</b> , 205, 12-27	6.2	1
279	Insulin Signaling in Arthritis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 672519	8.4	2
278	POS1349 THE JOINT INVOLVEMENT IN ADULT ONSET STILL'S DISEASE IS CHARACTERISED BY A PECULIAR MAGNETIC RESONANCE IMAGING AND A SPECIFIC TRANSCRIPTOMIC PROFILE. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 957.1-957	2.4	
277	POS0326 ROLE OF THE IL-25 / IL-17RB AXIS IN TH9 POLARIZATION IN PATIENTS WITH PROGRESSIVE SYSTEMIC SCLEROSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 390-391	2.4	0

276	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1498-1501	2.4	1
275	POS0177 POTENTIAL INVOLVEMENT OF IL-40 AND IL-40-PRODUCING CELLS IN PRIMARY SJOGREN'S SYNDROME (pSS) AND pSS-ASSOCIATED LYMPHOMA. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 301.2-302	2.4	0
274	Association Between Minor Salivary Gland Biopsy During Sjögren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 686457	8.4	3
273	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , <b>2021</b> , 11, 12455	4.9	3
272	Isolated "puffy hands" following COVID-19: clue to a long-term capillary leakage syndrome?. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 3863-3864	3.9	2
271	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 668173	4.9	3
270	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , <b>2021</b> , 60, 728-736	3.9	4
269	Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 179-187	4.1	0
268	Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. <i>Rheumatology International</i> , <b>2021</b> , 41, 129-137	3.6	3
267	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102738	13.6	14
266	Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102735	13.6	27
265	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2021</b> , 60, 1364-1375	3.9	10
264	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , <b>2021</b> , 60, 4558-4567	3.9	4
263	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab015	1.1	0
262	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , <b>2021</b> , 60, 4844-4849	3.9	7
261	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211037178	3.8	0
260	Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
259	The Pathogenic Role of Interferons in the Hyperinflammatory Response on Adult-Onset Still's Disease and Macrophage Activation Syndrome: Paving the Way towards New Therapeutic Targets. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3

258	Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. <i>Advances in Rheumatology</i> , <b>2021</b> , 61, 45	3	1
257	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 213	5.7	4
256	Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	9
255	Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 737573	4.9	5
254	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 187-195	2.2	6
253	Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 403-406	2.2	3
252	The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 792846	4.9	0
251	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 166-174	2.2	0
250	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 133, 166-174	2.2	
249	Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. <i>BMC Rheumatology</i> , <b>2020</b> , 4, 65	2.9	39
248	The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 1205-1215	5.1	10
247	Cytokine storm syndrome in severe COVID-19. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102562	13.6	57
246	Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1515-1516	2.4	21
245	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1130	8.4	51
244	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 1936960	4.3	5
243	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 151	5.7	13
242	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 127	5.7	11
241	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 42	4.9	6

240	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 409-420	5.1	6
239	Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102524	13.6	137
238	The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still's disease. A systematic review and meta-analysis of observational studies. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20933133	3.8	4
237	Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	2
236	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235326	3.7	15
235	Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 785-796	4	4
234	THU0265 THYMIC STROMAL LYMPHOPOIETIN (TSLP) AS A BIOMARKER OF PRIMARY SJÖGREN'S SYNDROME (PSS) AND RELATED LYMPHOMA: VALIDATION IN INDEPENDENT COHORTS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 359.1-360	2.4	1
233	Budget Impact Analysis of anakinra in the treatment of patients with Still's Disease. <i>Global &amp; Regional Health Technology Assessment</i> , <b>2020</b> , 7, 72-80	0.2	1
232	Advanced diagnostic imaging and intervention in tendon diseases. <i>Acta Biomedica</i> , <b>2020</b> , 91, 98-106	3.2	1
231	Diagnostic and interventional radiology fundamentals of synovial pathology. <i>Acta Biomedica</i> , <b>2020</b> , 91, 107-115	3.2	1
230	Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 593-604	3.8	5
229	Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study. <i>Clinical and Experimental Medicine</i> , <b>2020</b> , 20, 31-37	4.9	3
228	Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome. <i>Journal of Internal Medicine</i> , <b>2020</b> , 287, 214-215	10.8	1
227	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 119-128	5.1	4
226	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2020</b> , 59, 2350-2359	3.9	24
225	Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease" by Muraviov and Muraviova. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	2
224	Levels and Factors Associated with Resilience in Italian Healthcare Professionals during the COVID-19 Pandemic: A Web-Based Survey. <i>Behavioral Sciences (Basel, Switzerland)</i> , <b>2020</b> , 10,	2.3	7
223	Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study. <i>Spinal Cord Series and Cases</i> , <b>2020</b> , 6, 69	1.4	11

222	Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1152-1155	2.4	23
221	Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. <i>Scientific Reports</i> , <b>2020</b> , 10, 12232	4.9	21
220	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1588-1594	3.4	38
219	Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102662	13.6	4
218	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8562485	4.3	13
217	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 867-882	4.4	9
216	Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 931-942	5.1	0
215	Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences' by Ruscitti ' by Chen. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	0
214	Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e53	2.4	3
213	Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 692-697	2.8	3
212	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. <i>Rheumatology International</i> , <b>2020</b> , 40, 951-958	3.6	14
211	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. <i>Rheumatology International</i> , <b>2020</b> , 40, 107-113	3.6	10
210	An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 107-114	2.2	6
209	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 245-256	2.2	1
208	Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 53-56	2.2	
207	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 85-94	2.2	1
206	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 189-194	2.2	
205	Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 1247-1254	2.2	20

204	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCES) cohort <b>2020</b> , 15, e0235326		
203	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCES) cohort <b>2020</b> , 15, e0235326		
202	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCES) cohort <b>2020</b> , 15, e0235326		
201	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCES) cohort <b>2020</b> , 15, e0235326		
200	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCES (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 204	5.7	19
199	Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102369	13.6	38
198	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 918	5.6	13
197	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002901	11.6	57
196	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211142	3.7	8
195	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. <i>Cardiology Research and Practice</i> , <b>2019</b> , 2019, 2748035	1.9	3
194	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. <i>Scientific Reports</i> , <b>2019</b> , 9, 7144	4.9	12
193	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 296	5.6	17
192	Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	9
191	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. <i>Scientific Reports</i> , <b>2019</b> , 9, 4589	4.9	5
190	The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 501-509	13.6	17
189	Post-Translational Modifications of Proteins: Novel Insights in the Autoimmune Response in Rheumatoid Arthritis. <i>Cells</i> , <b>2019</b> , 8,	7.9	21
188	Laboratory Assessment of Patients with Suspected Rheumatic Musculoskeletal Diseases: Challenges and Pitfalls. <i>Current Rheumatology Reviews</i> , <b>2019</b> , 15, 27-43	1.6	3
187	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). <i>Molecular Medicine Reports</i> , <b>2019</b> , 20, 1488-1498	2.9	7

186	IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study. <i>Medicine (United States)</i> , <b>2019</b> , 98, e14587	1.8	21
185	Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoeidemiology. <i>Medicine (United States)</i> , <b>2019</b> , 98, e16399	1.8	5
184	Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 286	5.7	7
183	Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. <i>Medicine (United States)</i> , <b>2019</b> , 98, e15123	1.8	10
182	Inhibiting inflammatory cytokines in adult onset Still's disease. Current trends and new therapeutic perspectives. <i>Expert Opinion on Orphan Drugs</i> , <b>2019</b> , 7, 547-554	1.1	
181	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 93-106	13.6	63
180	T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modulated by hyperbaric oxygen therapy. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 116, 81-89	2.2	3
179	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 97-106	2.2	4
178	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 192-198	2.2	7
177	The Vessels Contribute to Fibrosis in Systemic Sclerosis. <i>Israel Medical Association Journal</i> , <b>2019</b> , 21, 471-474	4.74	7
176	Vitamin D increases the production of IL-10 by regulatory T cells in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 119, 76-81	2.2	6
175	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 864-872	4.1	50
174	Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1265-1275	9.5	10
173	The effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 399-404	13.6	16
172	Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 366-375	13.6	46
171	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. <i>Modern Rheumatology</i> , <b>2018</b> , 28, 922-932	3.3	11
170	Scleroderma fibroblasts suppress angiogenesis via TGF- $\beta$ /caveolin-1 dependent secretion of pigment epithelium-derived factor. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 431-440	2.4	14
169	H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. <i>Clinical and Experimental Immunology</i> , <b>2018</b> , 191, 220-228	6.2	27



168	A comprehensive review on adult onset Still's disease. <i>Journal of Autoimmunity</i> , <b>2018</b> , 93, 24-36	15.5	135
167	Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 102	4.9	38
166	The challenge to interpret conflicting results and the need of a univocal definition for germinal centres in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e31	2.4	3
165	Vitamin D and systemic lupus erythematosus - The hype and the hope. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 19-23	13.6	33
164	The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 290	4.9	10
163	Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. <i>Patient Preference and Adherence</i> , <b>2018</b> , 12, 2153-2168	2.4	13
162	Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , <b>2018</b> , 20, 81	4.9	23
161	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. <i>Journal of Immunology Research</i> , <b>2018</b> , 2018, 8410182	4.5	16
160	Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. <i>Rheumatology</i> , <b>2018</b> , 57, vii23-vii31	3.9	6
159	Histopathology of salivary glands. <i>Reumatismo</i> , <b>2018</b> , 70, 146-154	1.1	4
158	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 223	5.7	19
157	Pathogenesis of adult onset still's disease: current understanding and new insights. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 965-976	5.1	24
156	Downregulation of miRNA17-92 cluster marks VβVβ T cells from patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 236	5.7	11
155	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 73-79	2.2	2
154	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 102-112	2.2	34
153	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , <b>2017</b> , 37, 853-863	3.6	55
152	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1042-1050	2.4	73
151	Computed Tomography and MR Imaging in Rheumatoid Arthritis. <i>Radiologic Clinics of North America</i> , <b>2017</b> , 55, 997-1007	2.3	50

150	Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1179-1183	4.1	24
149	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1247-1260	2.3	10
148	Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Medicine (United States)</i> , <b>2017</b> , 96, e8180	1.8	15
147	PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis. <i>Nature Communications</i> , <b>2017</b> , 8, 1060	17.4	26
146	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 1041-1047	5.1	27
145	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study. <i>Medicine (United States)</i> , <b>2017</b> , 96, e7896	1.8	32
144	Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2839-2845	3.9	42
143	Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 1089-1097	5.1	31
142	Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 190, 208-216	6.2	19
141	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management.	13.6	84
140	Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systemic Sclerosis. <i>Cell Transplantation</i> , <b>2017</b> , 26, 841-854	4	23
139	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 251-260	3.9	16
138	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 16-21	13.6	49
137	Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets. <i>BMC Rheumatology</i> , <b>2017</b> , 1, 3	2.9	55
136	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 369	5.6	68
135	Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. <i>BioMed Research International</i> , <b>2017</b> , 2017, 7915340	3	19
134	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170108	3.7	32
133	Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181203	3.7	33

132	Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE). <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 24-32	2.2	8
131	Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 546-547	2.2	3
130	What could we learn from the sub-analysis of a single nation cohort in a worldwide study? Lessons from the results observed in the Italian cohort of the GO-MORE trial. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 623-629	2.2	4
129	THU0341 Correlation between Essdai and Clinessdai in A Real-Life Cohort of Sjögren's Syndrome Patients. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 310.2-310	2.4	0
128	AB0328 What Could We Learn from The Sub-Analysis of A Single Nation Cohort in A Worldwide Study? Lesson from The Results Observed in The Italian Cohort of The GO-MORE Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1013.2-1013	2.4	
127	Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1922-31	9.5	59
126	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1340-9	4.1	33
125	Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2348	9.5	
124	IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 849-55	5.1	39
123	Safety and efficacy of intra-articular anti-tumor necrosis factor β agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2016</b> , 29, 252-66	3	28
122	Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?'. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 202	13.6	
121	SAT0290 A Higher Disease Activity in Anti-Ssa/ssb Positive Sjögren's Syndrome Is Explained by A Higher Clinical and Biological B-Cell Activation. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 773.2-773	2.4	
120	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. <i>Archives of Medical Science</i> , <b>2016</b> , 12, 828-43	2.9	5
119	Novel Therapeutic Strategies in Sjögren's Syndrome: B-Cell Targeting <b>2016</b> , 273-289		
118	H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. <i>Clinical and Experimental Immunology</i> , <b>2016</b> , 186, 30-8	6.2	30
117	The CD68(+) /H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis. <i>Clinical and Experimental Immunology</i> , <b>2016</b> , 186, 30-8	6.2	23
116	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. <i>Clinical and Experimental Immunology</i> , <b>2016</b> , 184, 284-92	6.2	28
115	The Need to Target Mucosa-Associated Lymphoid Tissue for Preventing Lymphoma in Rheumatoid Factor-Positive Patients With Sjögren's Syndrome: Comment on the Article by Nocturne et al. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1318-9	9.5	3

114	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , <b>2016</b> , 14, 194	11.4	85
113	Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?. <i>Mechanisms of Ageing and Development</i> , <b>2016</b> , 159, 44-48	5.6	6
112	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 1683-9	3.9	52
111	Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 1123-1124	2.2	4
110	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , <b>2015</b> , 17, 832-49	4.8	14
109	Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 575-8	13.6	25
108	Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 1019-22	13.6	56
107	Interleukin-36 axis is modulated in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 181, 230-8	6.2	70
106	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , <b>2015</b> , 54, 792-7	3.9	55
105	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1808-16	4.1	60
104	A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. <i>Lupus</i> , <b>2015</b> , 24, 315-20	2.6	55
103	Stem cell therapies for systemic sclerosis. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 328-37	4.5	10
102	Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. <i>Scandinavian Journal of Rheumatology</i> , <b>2015</b> , 44, 36-41	1.9	38
101	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , <b>2015</b> , 1, 277-291	1.3	3
100	Interferon gamma-inducible protein 16 in primary Sjögren's syndrome: a novel player in disease pathogenesis?. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 208	5.7	20
99	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , <b>2015</b> , 9, 123	1.2	24
98	Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβI complex in systemic sclerosis dermal fibroblasts. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 247	5.7	18
97	Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjögren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 181, 219-29	6.2	36

96	FRI0437 Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from SSC Patients Induces an Anti Angiogenetic Effect, when Co-Cultured with Endothelial Cells. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 585.2-585	2.4	1
95	THU0393 IL-17 Producing Pathogenic T Lymphocytes Co-Express CD20 and are Depleted by Rituximab in Primary sjögren's Syndrome: A Novel Target for an Old Weapon. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 339.1-339	2.4	
94	Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. <i>Journal of Internal Medicine</i> , <b>2015</b> , 278, 185-92	10.8	71
93	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 $\beta$ via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for the pathogenesis of the disease. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 153, 25-34	6.2	78
92	Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 2160-8	4.6	7
91	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 243723	4.3	44
90	The role of IL-1 $\beta$ in the bone loss during rheumatic diseases. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 782382	4.3	103
89	SAT0377 Interferon Gamma-Inducible Protein 16 (IFI16) in Primary Sjögren's Syndrome: A Novel Player in Disease Pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 795.4-796	2.4	
88	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 1727-37	5.4	24
87	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 429-37	13.6	38
86	Myositis in primary Sjögren's syndrome: data from a multicentre cohort. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 457-64	2.2	26
85	CD4(-)CD8(-) T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement. <i>Journal of Autoimmunity</i> , <b>2014</b> , 51, 38-43	15.5	53
84	Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 49-55	3.9	68
83	Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 427-35	3.5	48
82	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting?. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 1167-73	13.6	29
81	Methotrexate: an old new drug in autoimmune disease. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 1519-30	5.1	75
80	Rituximab in primary Sjögren's syndrome: a ten-year journey. <i>Lupus</i> , <b>2014</b> , 23, 1337-49	2.6	19
79	The classification criteria for Sjögren syndrome: issues for their improvement from the study of a large Italian cohort of patients. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, e35	2.4	6

78	The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, e42	2.4	6
77	Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. <i>Journal of Autoimmunity</i> , <b>2014</b> , 51, 75-80	15.5	97
76	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 44, 314-24	5.3	54
75	Potential of stem cells in the treatment of rheumatic disease. <i>International Journal of Clinical Rheumatology</i> , <b>2014</b> , 9, 183-195	1.5	
74	Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2014</b> , 53, 1313-20	3.9	34
73	Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, R144	5.7	72
72	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. <i>Fibrogenesis and Tissue Repair</i> , <b>2014</b> , 7, 13		19
71	Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 442	5.7	36
70	The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 533-41	5.1	20
69	Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 709-16	13.6	42
68	Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). <i>European Journal of Radiology</i> , <b>2013</b> , 82, e268-73	4.7	57
67	Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. <i>Angiogenesis</i> , <b>2013</b> , 16, 595-607	10.6	54
66	Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 599-606	13.6	72
65	Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 173, 195-206	6.2	52
64	Jejunioileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 441-52	5.1	12
63	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R172	5.7	112
62	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 782-3	2.4	29
61	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 225-9	13.6	125

60	Inhibition of the complement system by glutathione: molecular mechanisms and potential therapeutic implications. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2011</b> , 24, 63-8	3	12
59	Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2011</b> , 24, 357-66	3	29
58	Cellular players in angiogenesis during the course of systemic sclerosis. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 641-6	13.6	39
57	Angiogenic cytokines and growth factors in systemic sclerosis. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 590-4	13.6	75
56	Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 595-8	13.6	140
55	A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 247-56		32
54	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1788-92	2.4	82
53	Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1852-7	4.1	35
52	The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 598-605	2.4	86
51	Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 408-11	2.4	23
50	Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. <i>Rheumatology</i> , <b>2009</b> , 48, 920-5	3.9	25
49	EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 163-8	2.4	75
48	Serologic profile and mortality rates of scleroderma renal crisis in Italy. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1464-9	4.1	33
47	The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 584-90	2.4	32
46	Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. <i>Rheumatology</i> , <b>2008</b> , 47, 646-51	3.9	62
45	Comment on: Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion: reply. <i>Rheumatology</i> , <b>2008</b> , 47, 1439-1440	3.9	
44	Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1994-2004		119
43	Vascular complications of scleroderma. <i>Autoimmunity Reviews</i> , <b>2007</b> , 6, 520-3	13.6	124

42	Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1107, 32-41	6.5	32
41	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 249-52	2.4	36
40	High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. <i>Rheumatology</i> , <b>2007</b> , 46, 1574-8	3.9	54
39	Variations of neuronal nitric oxide synthase in systemic sclerosis skin. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 202-13		16
38	Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3022-33		59
37	Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytes. <i>Scandinavian Journal of Rheumatology</i> , <b>2006</b> , 35, 346-50	1.9	11
36	High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. <i>American Journal of Reproductive Immunology</i> , <b>2006</b> , 55, 232-9	3.8	65
35	Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 2003-14	4.1	13
34	Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2005</b> , 7, R1244-53	5.7	6
33	Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemoinvasion and proliferation in rheumatoid arthritis synoviocytes. <i>Rheumatology</i> , <b>2005</b> , 44, 1255-62	3.9	14
32	Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis. <i>Rheumatology</i> , <b>2005</b> , 44, 607-13	3.9	14
31	The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). <i>Clinical and Experimental Rheumatology</i> , <b>2005</b> , 23, 671-7	2.2	11
30	Infliximab in spondyloarthritis associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 1664-9	2.4	92
29	Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. <i>Journal of Allergy and Clinical Immunology</i> , <b>2004</b> , 114, S51-131	11.5	490
28	Infection and Systemic Sclerosis <b>2004</b> , 613-622		2
27	Gamma/delta T cells in placenta and skin: their different functions may support the paradigm of microchimerism in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2004</b> , 22, S28-30	2.2	4
26	GM-CSF and pregnancy: evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment. <i>American Journal of Reproductive Immunology</i> , <b>2003</b> , 50, 232-7	3.8	56
25	Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study. <i>Lupus</i> , <b>2003</b> , 12, 735-40	2.6	41



24	Non organ based laboratory markers in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2003</b> , 21, S32-8	2.2	13
23	Microchimerism in Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2002</b> , 61, 1039-40	2.4	3
22	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. <i>Arthritis Research</i> , <b>2002</b> , 4, R11		192
21	Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 731-6	4.1	79
20	Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study. <i>Clinical and Experimental Rheumatology</i> , <b>2002</b> , 20, 365-72	2.2	10
19	Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. <i>Clinical and Experimental Immunology</i> , <b>2001</b> , 125, 310-5	6.2	30
18	Familial scleroderma: do environmental factors, genes and microchimerism share the same relevance?. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2001</b> , 15, 11-4	4.6	6
17	European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 592-8	2.4	223
16	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 585-91	2.4	65
15	Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 487-94	2.4	26
14	T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. <i>Clinical and Experimental Rheumatology</i> , <b>2001</b> , 19, 317-20	2.2	24
13	Impaired human ovarian follicular fluid complement function in hereditary angioedema. <i>Scandinavian Journal of Immunology</i> , <b>2000</b> , 51, 104-8	3.4	12
12	Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. <i>Gut</i> , <b>2000</b> , 47, 410-4	19.2	104
11	Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. <i>Clinical and Experimental Immunology</i> , <b>1999</b> , 115, 72-7	6.2	15
10	Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 327-34		66
9	The Italian version of the Family Assessment Device. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>1998</b> , 33, 451-61	4.5	32
8	Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD). <i>Clinical and Experimental Immunology</i> , <b>1998</b> , 111, 532-5	6.2	28
7	Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. <i>Clinical and Experimental Immunology</i> , <b>1997</b> , 108, 42-6	6.2	39

6	Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. <i>Journal of Rheumatology</i> , <b>1996</b> , 23, 291-6	4.1	29
5	Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , <b>1994</b> , 98, 83-8	6.2	45
4	Aerobiological survey in L'Aquila (Italy) throughout 1988 to 1990. <i>Aerobiologia</i> , <b>1992</b> , 8, 359-363	2.4	3
3	Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis. <i>Clinical and Experimental Immunology</i> , <b>1990</b> , 80, 360-5	6.2	18
2	Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. <i>Clinical and Experimental Immunology</i> , <b>1990</b> , 81, 368-72	6.2	58
1	Polyclonal B lymphocyte activation in progressive systemic sclerosis. <i>Journal of Clinical &amp; Laboratory Immunology</i> , <b>1989</b> , 29, 59-63		33